Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.
Salle R, Tubach F, Arlegui H, Curmin R, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, De Rycke Y, Jullien D, Mahé E, Paul C, Richard MA, Bachelez H, Zago M, Chosidow O, Sbidian É; PsoBioTeq. Salle R, et al. Among authors: arlegui h. Clin Exp Dermatol. 2023 Oct 25;48(11):1238-1246. doi: 10.1093/ced/llad233. Clin Exp Dermatol. 2023. PMID: 37409606
Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
Aubert H, Arlegui H, De Rycke Y, Bachelez H, Beylot-Barry M, Dupuy A, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Sbidian E, Viguier M, Chosidow O, Tubach F, Bénéton N; PsoBioTeq Study Group. Aubert H, et al. Among authors: arlegui h. Br J Dermatol. 2023 Jan 23;188(1):150-152. doi: 10.1093/bjd/ljac024. Br J Dermatol. 2023. PMID: 36689510 No abstract available.
Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort.
Arlegui H, Mahé E, Richard MA, De Rycke Y, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Bachelez H, Sbidian É, Chosidow O, Paul C, Tubach F; PSOBIOTEQ study group. Arlegui H, et al. Ann Dermatol Venereol. 2023 Jun;150(2):101-108. doi: 10.1016/j.annder.2023.01.005. Epub 2023 Feb 15. Ann Dermatol Venereol. 2023. PMID: 36914553 Free PMC article.
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
Bettuzzi T, Bachelez H, Beylot-Barry M, Arlégui H, Paul C, Viguier M, Mahé E, Beneton N, Jullien D, Richard MA, Joly P, Tubach F, Dupuy A, Sbidian E, Chosidow O; PsoBioTeq study group. Bettuzzi T, et al. Among authors: arlegui h. Acta Derm Venereol. 2022 Mar 8;102:adv00665. doi: 10.2340/actadv.v101.566. Acta Derm Venereol. 2022. PMID: 34806759 Free PMC article.
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Assan F, Tubach F, Arlegui H, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Bachelez H, Giboin C, Chosidow O, Sbidian E; and Psobioteq. Assan F, et al. Among authors: arlegui h. Dermatology. 2021;237(3):338-346. doi: 10.1159/000513398. Epub 2021 Feb 3. Dermatology. 2021. PMID: 33535213